Stockscreener 앱 받기
0.5936
2.69%
-0.0164
시간 외 거래:
.63
0.0364
+6.13%
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
HC Wainwright Reiterates “Buy” Rating for Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
H.C. Wainwright maintains Unicycive Buy rating, $7.50 target By Investing.com - Investing.com Canada
Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate - TipRanks
Unicycive Presents New Patient-Level Data Underscoring - GlobeNewswire
Breakthrough: Unicycive's New Kidney Drug Cuts Pills in Half, 98% of Patients Report Easy Use - Stock Titan
Unicycive Therapeutics Inc Inc. (UNCY) Price Performance: A Technical Analysis Perspective - investchronicle.com
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - ACCESS Newswire
UNCY FY2025 EPS Lifted by Brookline Capital Management - Defense World
HC Wainwright Issues Pessimistic Estimate for UNCY Earnings - Defense World
Brookline Capital Management Weighs in on UNCY Q1 Earnings - Defense World
HC Wainwright Issues Positive Forecast for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price - Defense World
Unicycive stock target raised to $7.50 by H.C. Wainwright - Investing.com Canada
Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS - MarketBeat
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive Look: Unicycive Unveils Latest Kidney Disease Breakthroughs at Major Healthcare Conference - Stock Titan
Noble Financial Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY) - The Globe and Mail
Unicycive Therapeutics, Inc. SEC 10-K Report - TradingView
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
FDA to Review Unicycive's Kidney Disease Drug in June 2025: Key Financial Updates - Stock Titan
Unicycive Approaches Its First Approval, But In A Competitive Space - insights.citeline.com
Targeting Pressing Unmet Needs in Kidney Diseases with Unicycive Therapeutics CEO Dr. Shalabh Gupta - iHeart
Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday - Defense World
Unicycive to Highlight Patient Reported Outcomes Data at - GlobeNewswire
Revolutionary Dialysis Treatment Cuts Pill Burden in Half: Key Clinical Data Coming - StockTitan
Unicycive Therapeutics Inc (NASDAQ:UNCY) stock: Is this a flash in the pan today? - US Post News
Unicycive Therapeutics Inc (NASDAQ: UNCY) Is One Of The Hottest Stocks Right Now. - Stocks Register
Unicycive reports potential kidney disease treatment advance By Investing.com - Investing.com Nigeria
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360 - The Manila Times
Unicycive reports potential kidney disease treatment advance - Investing.com
Unicycive Therapeutics Announces the Publication of - GlobeNewswire
Groundbreaking Kidney Disease Treatment Shows 41% Better ResultsCan This Change Dialysis Patient Care? - StockTitan
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 51.6% in January - MarketBeat
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Loses Momentum, Closing at 0.57 - The Dwinnex
Investing in Unicycive Therapeutics Inc [UNCY]: What You Must Know - Knox Daily
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Is Expected To Breakeven In The Near Future - Simply Wall St
Should investors be concerned about Unicycive Therapeutics Inc (UNCY)? - US Post News
Short Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Rises By 25.4% - MarketBeat
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Gains Momentum, Closing at 0.61 - The Dwinnex
Unicycive Therapeutics' (UNCY) Buy Rating Reiterated at HC Wainwright - MarketBeat
Unicycive highlights challenges in phosphate management - MSN
Unicycive Therapeutics Inc (UNCY) Has A Gold Mine On Its Hands - Stocks Register
Unicycive Therapeutics (NASDAQ:UNCY) Earns “Buy” Rating from HC Wainwright - Defense World
Unicycive Therapeutics Announces the Publication of Patient - GlobeNewswire
Unicycive highlights challenges in phosphate management By Investing.com - Investing.com Australia
Unicycive Therapeutics Publishes Review on Patient Perspectives in Phosphate Management for Chronic Kidney Disease - Nasdaq
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science - GlobeNewswire Inc.
Here's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Situation - Yahoo Finance
Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update - MarketBeat
Unicycive Therapeutics’ (UNCY) Buy Rating Reiterated at HC Wainwright - Defense World
Unicycive Therapeutics Receives Notice of Non-Compliance from Nasdaq - Defense World
Unicycive Therapeutics (NASDAQ:UNCY) Receives "Buy" Rating from HC Wainwright - MarketBeat
Unicycive Therapeutics granted extension to meet Nasdaq compliance - Investing.com
Unicycive Therapeutics granted extension to meet Nasdaq compliance By Investing.com - Investing.com Canada
0.98%
5.78%
자본화:
|
볼륨(24시간):